Oscar Health Inc Stock (OSCR) Moved Up by 7.22% on Aug 14: What Investors Need To Know

Source Tradingkey

Oscar Health Inc (OSCR) moved up by 7.22%. The Insurance sector is up by 0.36%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Chubb Ltd (CB) up 0.28%; Progressive Corp (PGR) up 0.88%; Travelers Companies Inc (TRV) up 0.34%.

SummaryOverview

What is driving Oscar Health Inc (OSCR)’s stock price up today?

Oscar Health experienced strong upward price momentum, driven by market re-evaluation of its stellar second-quarter 2026 financial results and raised full-year profit outlook. Although initial post-earnings trading saw short-term profit-taking due to second-half Affordable Care Act marketplace churn concerns, buyers aggressively stepped back into the stock as market participants digested the company's record-setting performance. Second-quarter revenue expanded sharply year over year to surpass consensus estimates, while adjusted earnings per share significantly exceeded expectations, fueled by robust member expansion across key state markets and disciplined underwriting.

The company's operational trajectory provided substantial fundamental backing for the rally. Oscar Health achieved a record low selling, general, and administrative expense ratio, demonstrating enhanced operating leverage and efficiency gains from its proprietary technology platform. Furthermore, the medical loss ratio improved dramatically compared to the prior-year period, supported by disciplined pricing and favorable prior-period reserve development. Building on this momentum, management raised its full-year operating income guidance by a wide margin, cementing confidence in the health insurer's long-term earnings trajectory and ability to capture market share within individual health plan segments.

Market sentiment was further bolstered by favorable Wall Street reassessments, institutional buying, and technical momentum as the stock pushed past previous resistance levels to establish fresh 52-week highs. Investors are increasingly viewing temporary policy and administrative headwind concerns as manageable relative to the company's impressive underlying cash generation and expanding membership base. Anticipation surrounding upcoming institutional investor updates, combined with strong industry tailwinds in technology-enabled health management, continues to attract growth-oriented capital, keeping volatility high but decisively tilted to the upside.

Technical Analysis of Oscar Health Inc (OSCR)

Technically, Oscar Health Inc (OSCR) shows a MACD (12,26,9) value of -0.227, indicating a neutral signal. The RSI at 55.960 suggests neutral condition and the Williams %R at 17.650 suggests overbought condition. Please monitor closely.

Fundamental Analysis of Oscar Health Inc (OSCR)

Oscar Health Inc (OSCR) is in the Insurance industry. Its latest annual revenue is $11.70B, ranking 32 in the industry. The net profit is $-443.15M, ranking 137 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Hold, with an average price target of $28.92, a high of $39.00, and a low of $8.00.

More details about Oscar Health Inc (OSCR)

Company Specific Risks:

  • Heavy Executive Insider Share Liquidations: Recent SEC Form 144 filings, including an August 13 notice from director Jeffery H. Boyd to sell 288,513 common shares following over $109 million in insider liquidations in recent months, have amplified market concerns regarding executive sentiment.
  • Substantial Risk-Adjustment Balance Sheet Liabilities: SEC Form 8-K disclosures highlight a massive risk-adjustment payable liability of $4.94 billion as of June 30, 2026, exposing operating cash flows and net income to potential risk-pool re-estimations and settlement timing volatility.
  • Valuation Premium vs. Consensus Analyst Targets: Despite recent guidance adjustments, Wall Street maintains a consensus "Hold" rating with average price targets between $22.00 and $23.25, leaving the stock's premium price tag vulnerable to sudden pullbacks if growth or medical loss ratios underperform.
  • ACA Policy Uncertainty and Enhanced Subsidy Expiration Risks: Ongoing legislative ambiguity surrounding the upcoming expiration of enhanced Affordable Care Act (ACA) premium tax credits poses substantial disenrollment risks, which could degrade risk pools and increase margin volatility across key state exchanges.
Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Analysis Today: Gold Drops 1.32% Despite Lower Fed Rate-Hike Bets, Can $4,313 Support Hold? Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
Author  Naoufal Seddik
12 hours ago
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
placeholder
XAUUSD Gold Analysis: Gold Holds Above $4,350 Ahead of US Inflation Data Is $4,500 Next? Gold holds above $4,350 following weak US jobs data. As inflation reports approach and UBS eyes $5,000, can XAUUSD break resistance at $4,435 to rally toward $4,500?
Author  Naoufal Seddik
Aug 12, Wed
Gold holds above $4,350 following weak US jobs data. As inflation reports approach and UBS eyes $5,000, can XAUUSD break resistance at $4,435 to rally toward $4,500?
placeholder
Intel Price Forecast: Nvidia Picked Xeon 6, Invested $5B, Yet Analysts Still Trail INTCIntel Corporation (NASDAQ: INTC) sits at $140.05, holding firm on the ascending trendline within the 2H timeframe. The RSI indicator is currently reading 55.21, positioning it as neutral-
Author  TradingKey
Jul 02, Thu
Intel Corporation (NASDAQ: INTC) sits at $140.05, holding firm on the ascending trendline within the 2H timeframe. The RSI indicator is currently reading 55.21, positioning it as neutral-
placeholder
NVIDIA Price Forecast: Michael Burry Shorts NVDA, but Analysts See $299On July 1, NVIDIA (NASDAQ: NVDA) sits at $198.34, failing to break above the former support level that is now serving as resistance between $198 and $205 on the 2H chart's downward blue c
Author  TradingKey
Jul 02, Thu
On July 1, NVIDIA (NASDAQ: NVDA) sits at $198.34, failing to break above the former support level that is now serving as resistance between $198 and $205 on the 2H chart's downward blue c
placeholder
Meta Compute Launch Sends AI Compute Stocks Tumbling GloballyMeta’s plan to sell surplus computing power hit chip stocks hard on Wall Street. Meta’s own shares climbed nearly 9% on the news.The announcement flipped years of assumed AI compute scarcity into a su
Author  Beincrypto
Jul 02, Thu
Meta’s plan to sell surplus computing power hit chip stocks hard on Wall Street. Meta’s own shares climbed nearly 9% on the news.The announcement flipped years of assumed AI compute scarcity into a su
goTop
quote